Here are 5 anti-obesity drug stocks besides Novo Nordisk and Eli Lilly to watch into year-end

Novo Nordisk and Eli Lilly reign over the anti-obesity drug market, and don't expect this duopoly to end soon, analysts say. But other companies — both big and small — are hoping to grab a piece of this lucrative market. In a research note, Piper Sandler analyst Yasmeen Rahimi said the firm is tracking more than 150 studies with 78 agents in development. Some are expected to provide market-moving updates before the year draws to a close.

mountain Structure shares over the past three months. Risinger rates the stock an outperform, citing both the potential for this drug's success as well as the strength of the company's management. "We note that global peak annual utilization of oral GLP-1s could easily exceed 15M people, assuming compelling commercial profiles," Risinger wrote in a research note on Sept. 29. JMP analyst Jonathan Wolleben initiated coverage of Structure at a market outperform in mid-October.

España Últimas Noticias, España Titulares

Similar News:También puedes leer noticias similares a ésta que hemos recopilado de otras fuentes de noticias.

Cramer's week ahead: Federal Reserve meeting, Apple and Eli Lilly earningsCNBC’s Jim Cramer said he’ll be watching for a number of notable earnings reports next week, including Apple, Caterpillar and drug maker Eli Lilly.
Fuente: NBCNewYork - 🏆 270. / 63 Leer más »

Cramer's week ahead: Federal Reserve meeting, Apple and Eli Lilly earningsCNBC’s Jim Cramer said he’ll be watching for a number of notable earnings reports next week, including Apple, Caterpillar and drug maker Eli Lilly.
Fuente: nbcchicago - 🏆 545. / 51 Leer más »

Cramer's week ahead: Federal Reserve meeting, Apple and Eli Lilly earningsCNBC's Jim Cramer said he'll be watching for a number of notable earnings reports next week, including Apple, Caterpillar and drug maker Eli Lilly.
Fuente: CNBC - 🏆 12. / 72 Leer más »